ABDX vs. GENI, PRM, LLAI, VRCI, GDR, CHLL, TLY, BELL, STX, and SNG
Should you be buying Abingdon Health stock or one of its competitors? The main competitors of Abingdon Health include GENinCode (GENI), Proteome Sciences (PRM), LungLife AI (LLAI), Verici Dx (VRCI), genedrive (GDR), Chill Brands Group (CHLL), Totally (TLY), Belluscura (BELL), Shield Therapeutics (STX), and Synairgen (SNG). These companies are all part of the "medical" sector.
GENinCode (LON:GENI) and Abingdon Health (LON:ABDX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and community ranking.
Abingdon Health has higher revenue and earnings than GENinCode. Abingdon Health is trading at a lower price-to-earnings ratio than GENinCode, indicating that it is currently the more affordable of the two stocks.
In the previous week, GENinCode and GENinCode both had 1 articles in the media. GENinCode's average media sentiment score of 0.76 beat Abingdon Health's score of 0.00 indicating that Abingdon Health is being referred to more favorably in the news media.
GENinCode has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Abingdon Health has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500.
GENinCode and Abingdon Health both received 0 outperform votes by MarketBeat users.
41.6% of GENinCode shares are owned by institutional investors. Comparatively, 10.6% of Abingdon Health shares are owned by institutional investors. 29.5% of GENinCode shares are owned by insiders. Comparatively, 56.1% of Abingdon Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
GENinCode has a net margin of 0.00% compared to GENinCode's net margin of -41.82%. GENinCode's return on equity of -76.65% beat Abingdon Health's return on equity.
Summary
Abingdon Health beats GENinCode on 7 of the 12 factors compared between the two stocks.
Get Abingdon Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Abingdon Health Competitors List
Related Companies and Tools
